Medicenna Therapeutics Corp reported its latest earnings, matching expectations but continuing a trend of narrow losses.
On August 13, 2026, Medicenna Therapeutics Corp (MDNA.TO) released its financial results for the fiscal quarter ending June 30, 2026. The biotechnology firm reported an EPS of -$0.06, aligning precisely with analyst estimates. This marks the third consecutive quarter where the company has either met or exceeded expectations, despite ongoing challenges in achieving profitability.
Recent earnings trend
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeAdvertisement
Market cap
$40.61M
52W high
$1.97
52W low
$0.34
1W change
+11.39%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 627.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+627.3% Upside
Current Price
C$0.44
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
56.7%
Annualized
90-Day Vol
71.8%
Annualized
Trend (90d)
-0.0%
Annualized drift
90d Mean
C$0.44
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.44 | C$0.36 – C$0.54 |
| 60 trading days | C$0.44 | C$0.33 – C$0.58 |
| 90 trading days | C$0.44 | C$0.31 – C$0.62 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-12 | — | -0.0500 | — |
| 2026-06-30 | 2026-08-13 | -0.0600 | -0.0600 | +0.0% |
| 2026-03-31 | 2026-06-25 | -0.0500 | -0.0600 | +16.7% |
| 2025-12-31 | 2026-02-12 | -0.0500 | -0.0600 | +16.7% |
| 2025-09-30 | 2025-11-12 | -0.0600 | -0.0700 | +14.3% |
| 2025-06-30 | 2025-07-29 | -0.0600 | -0.0500 | -20.0% |
Advertisement
Investor takeaway: While Medicenna's earnings report shows stability in line with expectations, the ongoing negative EPS highlights the need for strategic advancements in its clinical programs to drive future growth. Investors should weigh the company’s promising pipeline against its current financial realities.
Bull case
Medicenna has consistently met earnings expectations, which may suggest improved operational efficiency. Additionally, the company’s ongoing clinical trials, particularly the promising MDNA11, could lead to significant breakthroughs and revenue opportunities soon.
Bear case
Even though Medicenna has met earnings expectations, it continues to report losses, with a trailing EPS of -$0.22. The lack of revenue generation, combined with a high market cap relative to its financial performance, poses risks for potential investors, especially in a competitive biotechnology landscape.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
